Akero Therapeutics is developing Efruxifermin (EFX), a therapeutic agent aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) by restoring metabolic balance in patients. The company conducts clinical trials to evaluate the efficacy of EFX in reversing the progression of this serious liver disease.
Funding
$366.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease characterized by metabolic imbalance, leading to liver inflammation and damage. Current treatments are limited, and there is a need for more effective therapies to reverse the progression of MASH and restore metabolic balance in patients.
Solution
Akero Therapeutics is developing Efruxifermin (EFX), a novel FGF21 analogue, as a potential treatment for MASH. EFX is designed to harness the natural biology of FGF21 to address MASH by restoring metabolic balance. The company is currently conducting Phase 3 clinical trials to evaluate the efficacy of EFX in pre-cirrhotic and compensated cirrhosis MASH patients. Akero is also exploring the potential of EFX to treat other serious metabolic diseases and is evaluating opportunities to expand their pipeline, leveraging their expertise in MASH and FGF21 biology.
Target Audience
The primary target audience includes patients with metabolic dysfunction-associated steatohepatitis (MASH) and healthcare providers specializing in hepatology and metabolic diseases.
Features
- Efruxifermin (EFX): A novel FGF21 analogue designed to treat MASH.
- Targets the underlying metabolic dysfunction associated with MASH.
- Currently in Phase 3 clinical trials for pre-cirrhotic (F2-F3) MASH.
- Currently in Phase 3 clinical trials for compensated cirrhosis (F4) due to MASH.
- Multi-modal investigational drug that holistically confronts MASH.